

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)



(10) International Publication Number
WO 2024/215130 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) A61K 45/06 (2006.01)
A61K 31/5377 (2006.01) A61P 35/00 (2006.01)
A61K 31/454 (2006.01)

(21) International Application Number:

PCT/KR2024/004911

(22) International Filing Date:

12 April 2024 (12.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2023-0048582 13 April 2023 (13.04.2023) KR

(71) Applicant: CYRUS THERAPEUTICS INC. [KR/KR];
5th floor, 4 Jeongui-ro 8-gil, Songpa-gu, Seoul 05836 (KR).

(72) Inventors: HAN, Wooseok; #6207-1204, 285 Wiryeg-
wangjang-ro, Hanam-si, Gyeonggi-do 13015 (KR). NAM,
Joonwoo; #210-2003, 122 Dongpangyo-ro, Bundang-gu,
Seongnam-si, Gyeonggi-do 13527 (KR). JOO, Min Sung;
#104-701, 275 Dongpangyo-ro, Bundang-gu, Seongnam-si,
Gyeonggi-do 13489 (KR). KI, Dong Hyuk; #203-2504,
11 Byeoryang-ro, Gwachon-si, Gyeonggi-do 13839 (KR).
KIM, Eun-Jung; #202, 38 Gangnam-daero 2-gil, Seo-


cho-gu, Seoul 06788 (KR). LEE, JaeYung; #B-503, 15
Yeonseo-ro 37ga-gil, Eunpyeong-gu, Seoul 03339 (KR).

(74) Agent: SUNJUNG IP LAW LLP; 4th floor, Myungji
Building, 13, Teheran-ro 69-gil, Gangnam-gu, Seoul 06160
(KR).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: NOVEL GSPT1 DEGRADER AND USE THEREOF



(57) Abstract: The present disclosure relates to a novel GSPT1 degrader and a use thereof. Specifically, the present disclosure relates to a compound represented by Formula I, a stereoisomer, hydrate, solvate, or pharmaceutically acceptable salt thereof, a pharmaceutical composition for treating a disorder of uncontrolled cell proliferation comprising the same, and a method of treating a disorder of uncontrolled cell proliferation by administering the same to a mammal. The compound according to the present disclosure exhibits high selectivity and sustained degradation activity against GSPT1, excellent pH stability, and low cytotoxicity against normal cells, and thus has excellent anticancer efficacy and a high therapeutic index. In addition, the compound according to the present disclosure can exhibit excellent anticancer activity against a cancer with a neuroendocrine phenotype, such as small cell lung cancer (SCLC), lung neuroendocrine cancer (NEC), and neuroendocrine prostate cancer (NEPC).

WO 2024/215130 A1

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*